Cipher Pharmaceuticals Inc.
CPHRF
$10.44
$0.242.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.75% | 152.28% | 104.86% | 140.28% | 70.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.75% | 152.28% | 104.86% | 140.28% | 70.90% |
| Cost of Revenue | 19.19% | 125.86% | 172.89% | 437.07% | 83.09% |
| Gross Profit | 24.82% | 159.24% | 89.94% | 68.80% | 68.27% |
| SG&A Expenses | -19.35% | 210.17% | 228.54% | 274.65% | 172.49% |
| Depreciation & Amortization | -6.65% | 518.84% | 530.45% | 453.48% | 615.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.54% | 209.02% | 239.44% | 350.33% | 179.15% |
| Operating Income | 165.99% | 92.78% | -19.02% | -85.90% | -38.14% |
| Income Before Tax | 1,206.13% | 154.67% | -36.42% | -177.53% | -89.56% |
| Income Tax Expenses | -2,990.70% | 206.67% | 62.30% | -55.96% | 101.10% |
| Earnings from Continuing Operations | 1,843.82% | 96.76% | -46.70% | -56.32% | -95.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,843.82% | 96.76% | -46.70% | -56.32% | -95.97% |
| EBIT | 165.99% | 92.78% | -19.02% | -85.90% | -38.14% |
| EBITDA | 78.37% | 135.96% | 28.47% | -34.55% | 15.28% |
| EPS Basic | 1,835.71% | 83.41% | -50.05% | -58.81% | -95.97% |
| Normalized Basic EPS | 115.47% | 113.38% | -36.35% | -151.27% | -38.78% |
| EPS Diluted | 2,000.00% | 83.33% | -50.00% | -57.17% | -96.30% |
| Normalized Diluted EPS | 114.69% | 112.08% | -36.71% | -152.37% | -39.00% |
| Average Basic Shares Outstanding | 0.80% | 7.28% | 6.74% | 6.05% | -0.53% |
| Average Diluted Shares Outstanding | 0.99% | 7.89% | 7.41% | 3.81% | -0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |